MNMD

Mind Medicine (MindMed), Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website mindmed.co
Employees(FY) 48
ISIN CA60255C8850

Performance

-5.56%

+1.34%

+7.1%

-20.4%

-2.44%

YTD

+75.91%

Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of MNMD 2025-01-31

The stock indicators reflect a bearish sentiment, with a Moving Average Score of 10, an Oscillators Score of 43, and a Technical Score of 15, indicating overall weakness in momentum and trend direction. The low scores suggest that caution is warranted for potential investors, as the market appears to be under pressure.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MNMD

Stock Rank

Recent News & Updates

2025-01-31 07:20
Mind Medicine doses first patient in Panorama study(TipRanks)
2025-01-30 07:00
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder(Business Wire)
2025-01-29 18:00
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder(Businesswire)
2025-01-20 10:48
Weekly Roundup on the Cannabis Sector & Psychedelic Sector(Market Exclusive)
2024-12-19 07:00
MindMed to Be Added to the Nasdaq Biotechnology Index(Business Wire)
2024-12-18 18:00
MindMed to Be Added to the Nasdaq Biotechnology Index(Businesswire)
2024-12-16 07:00
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)(Business Wire)
2024-12-15 18:00
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)(Businesswire)
2024-12-11 07:00
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress(Business Wire)
2024-12-10 18:00
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress(Businesswire)
2024-12-05 07:00
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)(Business Wire)
2024-12-04 18:00
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)(Businesswire)
2024-12-03 07:00
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy(Business Wire)
2024-12-02 18:00
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy(Businesswire)
2024-12-02 07:00
MindMed Announces New Employee Inducement Grants(Business Wire)
2024-12-01 18:00
MindMed Announces New Employee Inducement Grants(Businesswire)
2024-11-18 07:00
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer(Business Wire)
2024-11-17 18:00
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer(Businesswire)
2024-11-14 07:26
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions(Simply Wall St.)
2024-11-13 07:00
MindMed to Participate in Upcoming Investor Conferences(Business Wire)
2024-11-12 18:00
MindMed to Participate in Upcoming Investor Conferences(Businesswire)
2024-11-07 16:01
MindMed Reports Third Quarter 2024 Financial Results and Business Updates(Business Wire)
2024-11-07 03:01
MindMed Reports Third Quarter 2024 Financial Results and Business Updates(Businesswire)
2024-10-24 07:00
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update(Business Wire)
2024-10-23 19:00
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update(Businesswire)
2024-10-12 06:05
Mind Medicine assumed with an Outperform at Leerink(Yahoo Finance)
2024-09-09 16:01
MindMed Announces New Employee Inducement Grants(Business Wire)
2024-09-09 04:01
MindMed Announces New Employee Inducement Grants(Businesswire)
2024-09-04 07:00
MindMed to Participate in September Investor Conferences(Business Wire)
2024-09-03 19:00
MindMed to Participate in September Investor Conferences(Businesswire)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.